Summary
How ADRX maps according to Revere
| Sector Level | Count |
|---|---|
Industries
|
1 |
Sectors
|
4 |
Subsectors
|
17 |
Product/Service Groups
|
71 |
Specific product example for ADRX
| Product Hierarchy |
|---|
|
*Healthcare
|
|
Biopharmaceuticals
|
|
Allergies
|
Upper Respiratory
|
|
Antihistamines
|
Company Highlights:
Market Cap.
|
1,805.377 |
|
Current Shares Outstnd.
|
73.9 |
| Contact Name | Angelo C. Malahias |
| Contact Phone | (954)5840300 |
| City, State | Davie, FL |
| Dividends Per Common Share | 0.00 |
| Dividend Yield | 0.00 |
|
SI %SHOUT
|
5.75 |
|
IH % Shares Outst.
|
85.48% |
| Number of Employees | 1,680 |
| Revenue Per Employee | 608,216.4 |
| Book Value Per Share | 10.45 |
| 5 Year CAGR in Revenues % | 14.92 |
| 5 Year CAGR in Earnings % | -2.22 |
|
Asset Turnover
|
0.23 |
| Fiscal Year End | 12/31/2006 |
| Next Reporting Period | Sep, 2006 |
Business Description:
Andrx Corporation is a pharmaceutical company that operates in four segments. The Distributed Products segment distributes primarily generic pharmaceuticals manufactured largely by others, as well as by Andrx, from its Weston, Florida and Groveport, Ohio distribution facilities. Through the Generic Products segment, the Company researches, develops, manufactures and sells generic versions of selected controlled-release pharmaceuticals, utilizing its drug delivery technologies, as well as generic versions of immediate-release and oral contraceptive products, primarily to a limited number of large pharmaceutical wholesalers and warehousing pharmacy chains. Through the Brand Products segment, the Company develops and commercializes brand name pharmaceuticals, in many cases, using its controlled-release drug delivery technologies. The Contract Services segment is pursuing the development and manufacture of pharmaceutical products for other pharmaceutical companies.
Chart:
| Last Price | 24.43 |
| Price Chg. | 0.00 |
| Price Chg. % | 0.00% |
| Open Price | 24.49 |
| High Price | 24.50 |
| Low Price | 24.35 |
| 52w High Price | 24.65 |
| 52w Low Price | 14.35 |
| Volume | 908,241 |
| 30d Avg. Volume | 833,832 |
* Quotes delayed 20 minutes.
Products
| Products Manufactured/Services Performed Details |
|---|
|
*Healthcare
|
|
Biopharmaceuticals
|
|
Allergies
|
|
Upper Respiratory
|
Antihistamines
Products:
|
Antihistamines/Decongestants
Products:
|
|
Cardiovascular System
|
|
Heart Disorders
|
|
Angina
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Products:
|
Calcium Channel Blocking Agents
Products:
|
|
Heart Failure (HF)
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Products:
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Products:
|
|
Vascular Disorders
|
|
Atherosclerosis
|
HMG CoA Reductase Inhibitors (Statins)
Products:
|
|
Hypertension
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Products:
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Products:
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Products:
|
Calcium Channel Blocking Agents
Products:
|
|
Peripheral Vascular Disease
|
Blood Viscosity Reducing Agents
Products:
|
|
Digestive System
|
|
Gastrointestinal Tract Disorders
|
|
Gastroduodenal Disorders
|
|
Peptic Ulcers
|
|
Duodenal
|
H2 Receptor Antagonists
Products:
|
Proton Pump Inhibitors
Products:
|
|
Gastric
|
H2 Receptor Antagonists
Products:
|
Proton Pump Inhibitors
Products:
|
|
Zollinger-Ellison Syndrome
|
H2 Receptor Antagonists
Products:
|
Proton Pump Inhibitors
Products:
|
|
Gastroesophageal Disorders
|
|
Acid Indigestion/Heartburn
|
H2 Receptor Antagonists
Products:
|
|
Erosive Esophagitis
|
Proton Pump Inhibitors
Products:
|
|
Gastroesophageal Reflux Disease (GERD)
|
H2 Receptor Antagonists
Products:
|
Proton Pump Inhibitors
Products:
|
|
Endocrinology/Metabolism
|
|
Diabetes
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes
|
Biguanides
Products:
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products:
|
Insulin Stimulating Agents (Sulfonylureas)
Products:
|
|
Hyperglycemia
|
Insulin Stimulating Agents (Sulfonylureas)
Products:
|
|
Intermediary Metabolism Disorders
|
|
Gout
|
|
Gouty Arthritis
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Hypercholesterolemia
|
HMG CoA Reductase Inhibitors (Statins)
Products:
|
|
Hematology
|
|
Serum Factor Disorders
|
|
Hypercholesterolemia
|
HMG CoA Reductase Inhibitors (Statins)
Products:
|
|
Hyperglycemia
|
Insulin Stimulating Agents (Sulfonylureas)
Products:
|
|
Hypokalemia
|
Potassium Supplements
Products:
|
|
Immunology
|
|
Autoimmune Disorders
|
|
Arthritis
|
|
Rheumatoid Arthritis (RA)
|
|
Analgesics
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Infectious Diseases
|
|
Bacterial
|
|
Antibacterial Agents
|
|
Broad Spectrum
|
|
Antibiotics
|
Macrolides
Products:
|
|
Mycological (Fungal)
|
|
Antifungal Agents
|
|
Narrow Spectrum
|
|
Dermatology
|
|
Onychomycosis (Nail)
|
|
Amine Derivatives
|
Allyl
Products:
|
|
Musculoskeletal System
|
|
Skeletal Disorders
|
|
Joint Disorders
|
|
Ankylosing Spondylitis
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Gouty Arthritis
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Osteoarthritis (OA)
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Rheumatoid Arthritis (RA)
|
|
Analgesics
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Neurology
|
|
Neurological Disorders
|
|
Epilepsy
|
|
Partial Seizures
|
|
Complex
|
|
Adjunctive Therapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
|
Monotherapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
|
Primary Generalized Seizures
|
|
Absence (Petit Mal)
|
|
Adjunctive Therapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
|
Monotherapy
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
|
Headaches
|
|
Vascular (Migraine)
|
|
Prophylactic Treatments
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
|
Psychiatric Disorders
|
|
Anxiety
|
|
Generalized Anxiety Disorder (GAD)
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Obsessive Compulsive Disorder (OCD)
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Panic Disorder
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Post-Traumatic Stress Disorder (PTSD)
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Social Anxiety Disorder (SAD)
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Childhood/Adolescent Disorders
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)
|
Dopamine Receptor Blocking Agents
Products:
|
|
Eating Disorders
|
|
Bulimia
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Mood Disorders
|
|
Bipolar Disorders (Manic Depressive Disorders)
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Products:
|
|
Depression
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
Tetracyclic Compounds
Products:
|
|
Premenstrual Dysphoric Disorders
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Products:
|
|
Obstetrics/Gynecology
|
|
Child Birth/Pregnancy
|
|
Prevention (Contraception)
|
|
Contraceptives (Birth Control)
|
Estrogens/Progestins
Products:
|
|
Pain Management
|
|
Narcotics
|
Analgesics/Opioids
Products:
|
Opioids
Products:
|
|
Non-Narcotics
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Products:
|
|
Respiratory System
|
|
Lower Respiratory Tract Disorders (Lung Disorders)
|
|
Asthma
|
|
Acute Treatments
|
|
Bronchodilators
|
Beta Adrenergic Receptor Agonists
Products:
|
|
Bronchitis
|
|
Acute Treatments
|
|
Bronchodilators
|
Beta Adrenergic Receptor Agonists
Products:
|
|
Bronchospasm
|
|
Bronchodilators
|
Beta Adrenergic Receptor Agonists
Products:
|
|
Chronic Obstructive Pulmonary Disease (COPD)
|
|
Acute Treatments
|
|
Bronchodilators
|
Beta Adrenergic Receptor Agonists
Products:
|
|
Upper Respiratory Tract Disorders
|
|
Coughs/Colds
|
Decongestants/Expectorants
Products:
|
|
Toxicology
|
|
Substance Abuse
|
|
Withdrawal
|
|
Nicotine (Smoking Cessation)
|
Serotonin/Norepinephrine Reuptake Inhibitors
Products:
|
|
Healthcare Services
|
|
Distributors
|
|
Pharmaceutical
|
Specialty/Generic
Products:
|
|
Nutritional Health
|
|
Dietary/Naturopathic Supplements
|
Women`s Health
Products:
|
|
Outsourced Services
|
|
Development/Manufacturing Services
|
|
Contract Manufacturing Organizations (CMO)
|
|
Pharmaceuticals
|
Active/Intermediate Chemicals
Products:
|
|
Drug Delivery Technology
|
|
Oral Delivery
|
Hydrogel Based
Products:
|
Hydrogel Based/Polymer Coated
Products:
|
Osmotic
Products:
|
Polymer Coated
Products:
|
Key Financials
FY Ends December
| Period Length/End |
3 months ending 06/30/2006 |
3 months ending 03/31/2006 |
3 months ending 06/30/2005 |
12 months ending 12/31/2005 |
12 months ending 12/31/2004 |
12 months ending 12/31/2003 |
| Total Revenue | 254.8 | 241.4 | 261.7 | 1,042.0 | 1,145.8 | 1,046.3 |
|
Gross Margin %
|
20.26 | 14.07 | 23.72 | 25.03 | 30.21 | 32.7 |
|
Operating Income
|
-2.4 | -23.0 | 10.4 | 9.6 | 88.1 | 67.9 |
|
Operating Margin %
|
-0.93 | -9.53 | 3.98 | 0.92 | 7.69 | 6.49 |
| Tax Rate % | 35.47 | 34.9 | 38 | -198.97 | 30.2 | 38.4 |
| Income After Taxes | 1.4 | -12.0 | 8.0 | 62.5 | 65.7 | 48.2 |
| Net Income Margin % | 0.56 | -4.97 | 3.06 | 5.99 | 5.73 | 4.6 |
|
F.D. EPS - Incl. Xord. Items
|
0.02 | -0.15 | 0.11 | 0.85 | 0.89 | 0.66 |
| Book Value Per Share | 10.45 | 10.41 | 10.22 | 10.56 | 9.58 | 8.61 |
Ratios
|
P/R Ratio (TTM)
|
1.80 |
|
P/E Ratio (TTM)
|
194.86 |
| Price To Free Cash Flow (TTM) | 805.34 |
| Price To Book Value | 2.32 |
| Net Assets to Market Cap. % | 61.44% |
| Beta | 1.41 |
|
Days to Sell Inventory
|
101.8 |
|
Current Ratio
|
3.79 |
|
Quick Ratio
|
2.15 |
| Interest Coverage | n/a |
| Debt to Market Cap. % | 0.00% |
| Return on Equity % | 1.11 |
| Return on Assets % | 0.76 |
| Return on Invested Capital % | -0.18 |
Major Competitors
| Name | Trailing Revenue | P/R Ratio (TTM) | P/E Ratio (TTM) | 1 Year Return % | Overlap |
|---|---|---|---|---|---|
AmerisourceBergen Corp.
|
59,478.5 | 0.15 | 24.94 | 17.07% | 1 |
|
Cardinal Health, Inc.
|
81,363.6 | 0.33 | 26.66 | 4.08% | 3 |
|
McKesson Corporation
|
90,608.0 | 0.17 | 20.66 | 11.15% | 1 |
| Average | 77,150.0 | 0.22 | 24.09 | 10.77% | 2 |
Notes:
- The company competes with other wholesalers & distributors of generic and branded pharmaceutical products.
Customers
| Name | Last Quarter Financial Stats | 1 YR Price Performance % | |||
|---|---|---|---|---|---|
| Y/Y Revenue Growth % | Sequential Revenue Growth % | Y/Y Margin Growth % | Sequential Margin Growth % | ||
|
Impax Laboratories Inc.
|
86.12 | 0.46 | n/a | 45.10 | -41.86% |
|
Sciele Pharma Inc.
|
45.33 | 8.95 | -15.08 | 3.11 | -5.37% |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
77.02 | 29.89 | 18.51 | n/a | 1.31% |
|
Tyco International Ltd.
|
5.07 | -46.67 | -31.85 | -5.53 | 1.30% |
| Average | 53.39 | -1.84 | -9.48 | 14.22 | -11.16% |
Notes:
- The company develops & commercializes generic versions of controlled-release brand name pharmaceuticals, generic versions of niche & immediate-release pharmaceutical products and brand name pharmaceuticals. It serves independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. No single customer accounted for 10% or more of the company's total revenues for the fiscal year ended December 31, 2005.
Strategic Partners
| Name | Subtypes | 1 YR Price Performance % |
|---|---|---|
|
Able Laboratories Inc.
|
Supplier | -98.80% |
|
Amphastar Pharmaceuticals, Inc.
|
Supplier | n/a |
|
Elan Corporation, plc (ADR)
|
In-licensing, Supplier | 77.07% |
|
Impax Laboratories Inc.
|
Distribution, Out-licensing | -41.86% |
|
InvaGen Inc.
|
Manufacturing | n/a |
|
Johnson & Johnson
|
In-licensing, Supplier | 1.87% |
|
Merck KGaA
|
In-licensing, Marketing | n/a |
|
Novartis AG (ADR)
|
In-licensing, Supplier | 15.79% |
|
Perrigo Company
|
Distribution, Marketing | 17.93% |
|
Pfizer Inc.
|
In-licensing, Supplier | 13.03% |
|
Ranbaxy Laboratories Ltd.
|
Supplier | n/a |
|
Schwarz Pharma, Inc.
|
Marketing, Out-licensing | 86.12% |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
Marketing, Out-licensing, Research Collaboration | 1.31% |
|
Tyco International Ltd.
|
Marketing, Out-licensing, Supplier | 1.30% |
|
Watson Pharmaceuticals, Inc.
|
Joint Venture | -26.45% |
Business/Geographical Segments
Business Segments
Source:
10-Q Aug 09, 2006
| External Revenue | Total Revenue | Depreciation | Operating Income/Loss | Operating Margin (%) | Interest Income, Non-Operating | Equity In Affiliates | Total Assets | Operating Return on Assets (%) | Purchase of Fixed Assets | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Distributed Products | 177.5 | 69.7% | 177.5 | 69.7% | 0.4 | 5.6% | 10.3 | 84.9% | 5.80% | 0.0 | 0.0 | 0.0% | 258.9 | 40.3% | 3.98% | 0.0 | 0.2% | |
| Bioequivalent Products | 68.6 | 26.9% | 68.6 | 26.9% | 6.9 | 87.4% | 1.4 | 11.8% | 2.09% | 0.0 | 0.6 | 100.0% | 364.9 | 56.7% | 0.39% | 8.1 | 99.8% | |
| Brand Products | 0.0 | 0.0% | 0.0 | 0.0% | 0.0 | 0.0% | 0.0 | 0.0% | 0.0 | 0.0 | 0.0% | 0.0 | 0.0% | 0.0 | 0.0% | |||
| Contract Services | 8.6 | 3.4% | 8.6 | 3.4% | 0.6 | 7.0% | 0.4 | 3.3% | 4.61% | 0.0 | 0.0 | 0.0% | 19.3 | 3.0% | 2.07% | 0.0 | 0.0% | |
| Segment Total | 254.7 | 100.0% | 254.7 | 100.0% | 7.9 | 100.0% | 12.1 | 100.0% | 4.76% | 0.0 | 0.6 | 100.0% | 643.1 | 100.0% | 1.89% | 8.2 | 100.0% | |
| Other | 0.0 | 0.0 | 1.6 | -14.5 | -55773.08% | 4.0 | 0.0 | 477.1 | -3.04% | 0.6 | ||||||||
| Consolidated Total | 254.8 | 254.8 | 9.5 | -2.4 | -0.93% | 4.0 | 0.6 | 1,120.2 | -0.21% | 8.7 | ||||||||